In the past decade, immune-engaging bispecific antibodies have risen to the forefront of blood cancer treatments. However, the bispecific design parameters used for maximizing therapeutic windows in blood cancers do not translate well to solid tumors.

To achieve efficacy without dose limiting toxicities, our immune-engaging bispecific antibodies are designed to eliminate solid tumors by tuning potencies of immune-engaging arms and driving tumor localization.  Our best-in-class therapeutics will provide clinicians flexibility with dosing strategies and combination regimens to deliver optimal results for patients.

NGS-based antibody discovery enables rapid development of diverse binding arm collections. Our fixed-light chain format allows for flexible pairing of immune effector and tumor targeting arms. Our proprietary functional and developability screens assess the desired set of potencies and identify clinically viable molecules.